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Abstract 
In atherosclerosis, vascular smooth muscle cells (SMCs) express class II major histocompatibility 
complex molecules (MHC class II) however, their ability to act as antigen presenting cells remains 
controversial. In the present study aortic murine SMC antigen presentation capacity was evaluated 
using the Ealpha (Eα)-GFP/Y-Ae system to visualize antigen uptake through a GFP tagged and 
tracking of Eα peptide/MHCII presentation using the Y-Ae Ab. Stimulation with IFN-γ (100 
ng/mL) for 72 h caused a significant (P<0.01) increase in the percentage of MHC class II positive 
SMCs, compared with unstimulated cells. Treatment with Eα-GFP (100 µg/mL) for 48 h induced a 
significant (P<0.05) increase in the percentage of GFP positive SMCs while it did not affect the 
percentage of Y-Ae positive cells, being indicative of antigen uptake without its presentation in the 
context of MHC class II. After IFN-γ-stimulation, ovalbumin (OVA, 1 mg/mL)- or OVA323-339 
peptide (0.5 µg/mL)-treated SMCs failed to induce OT-II CD4+ T cell activation/proliferation; this 
was also accompanied by a lack of expression of key costimulatory molecules (OX40L, CD40, 
CD70 and CD86) on SMCs. Finally, OVA-treated SMCs failed to induce DO11.10-GFP hybridoma 
activation, a process independent of costimulation. Our results demonstrate that while murine 
primary aortic SMCs express MHC class II and can acquire exogenous antigens, they fail to activate 
T cells through a failure in antigen presentation and a lack of costimulatory molecule expression. 
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1. Introduction 
Atherosclerosis is an immuno-inflammatory process [1, 2] in which smooth muscle cells (SMCs) 
play a critical role [3-5]. SMCs produce a broad range of immuno-inflammatory mediators 
contributing to vascular inflammation [6] and participate in the formation of arterial tertiary 
lymphoid tissue in experimental atherosclerosis [7]. Human SMCs express class II major 
histocompatibility complex molecules (MHC class II) in atherosclerotic plaques [8] and following 
IFN-γ stimulation [9-11]. In addition, SMC MHC class II expression increases following vascular 
injury in rodent models [12]. However, the possibility that SMCs can act as antigen presenting cells 
(APCs) and consequently activate vascular T cell response remains, to date, controversial. In mice it 
has been demonstrated that brain microvessel SMCs/pericytes can induce a proliferation of 
syngenic CD4+ T cells in vitro in a MHC class II dependent manner [13]. SMCs/pericytes were able 
to process and present exogenous antigens to T cell hybridoma [14] and preferentially activated Th1 
T cell clones as compared with Th2 T cells of the same antigen specificity [15]. In contrast to 
syngenic co-cultures using wild type CD4+ T cells, microvascular SMCs did not support 
proliferation of antigen specific T-cell receptor (TCR) transgenic CD4+ T cells [16]. Others 
demonstrated that murine SMCs pulsed with antigen increased the expression of the IL-2 receptor 
on T cells but were not able to induce T cell proliferation [17]. 
 Human saphenous vein SMCs expressing MHC class II molecules were unable to activate 
allogenic memory T cells [18] and failed to effectively support T-cell proliferation to the polyclonal 
activator, phytohemagglutinin [19]. This inability resulted from a defect in costimulatory function, 
particularly the lack of OX40 ligand (OX40L) [19]. SMCs from different tissues may behave 
differently, for example cultured human airway smooth muscle cells were capable of presenting the 
superantigen, staphylococcal enterotoxin A, via MHC class II molecules to CD4+ T cells [20]. More 
selective approaches are required to investigate SMC antigen presentation capacity. 
 Here we utilized the Eα-GFP/Y-Ae model that allows visualization of antigen uptake through a 
GFP tagged Eα peptide and tracking of antigen presentation using the Y-Ae Ab. The Eα-GFP 
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protein is internalized, processed by APCs to generate Eα peptide for presentation on MHC class II. 
The monoclonal Ab Y-Ae detects Eα only when bound to MHC Class II molecules (I-Ab) [21-24]. 
We demonstrate that while murine primary aortic SMCs express MHC class II and can acquire 
exogenous antigens, they fail to activate T cells through a failure in antigen presentation and a lack 
of costimulatory molecule expression. 
 
2. Materials and Methods 
2.1. Animals. C57BL/6 mice (Harlan, Shardlow, UK) were used to prepare SMCs and dendritic 
cells (DCs). OT-II (CD45.1) mice bred in house were used as donors of Tg T cells. These 
transgenic mice express the mouse alpha-chain and beta-chain T cell receptor that pairs with the 
CD4 coreceptor and is specific for chicken ovalbumin 323-339 in the context of I-Ab. Animals were 
maintained on a 12/12-hour light/dark cycle with free access to food and water and all the 
procedures were performed in accordance with local ethical and UK Home Office regulations. 
 
2.2. Cell cultures and co-cultures. Murine primary SMCs were derived from the thoracic aorta of 
C57BL/6 mice as previously described [25-26] and grown in DMEM supplemented with L-
glutamine, 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin (all from 
Gibco, Paisley, UK). Before initiation of the assays, the SMCs were starved into DMEM 
supplemented with 0.1% fetal bovine serum for 48 hours [25, 27]. Cells were characterized by 
immunofluorescence microscopy using FITC labeled anti-smooth muscle α-actin (α-SMA) 
monoclonal antibody (Ab) (clone 1A4; Sigma-Aldrich, Dorset, UK). Studies were performed with 
cells at passages 3-6. OVA specific TCR transgenic OT-II CD4+ T cell were isolated from OT-
II/CD45.1 mice using the MicroBead-based CD4+ T Cell Isolation Kit II (Miltenyi Biotec, Bisley, 
UK) according to manufacturer's instructions and grown in complete RPMI (containing L-
glutamine, 10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin). The 
DO11.10-GFP hybridoma cells [28] were grown in complete RPMI containing geneticin (0.5 
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mg/ml, Sigma-Aldrich) as previously described [29]. DCs were obtained by flushing the bone 
marrow of C57BL/6 mice and grown in complete RPMI containing 10% Granulocyte-Macrophage 
Colony Stimulating Factor (GM-CSF) for 7 days [30]. All cells used were kept in a humidified 
incubator at 37°C in 5% CO2. 
 Murine SMCs were cultured in 48 multi-well plates until 80% confluence. Subsequently cells 
were stimulated with IFN-γ (100 ng/mL; R&D Systems Abingdon, UK) for 72 h to enhance their 
MHC class II expression, then treated with OVA (1 mg/mL; InvivoGen, Toulouse, France) or 
OVA323-339 peptide (0.5 µg/mL; InvivoGen) overnight. Isolated OT-II CD4+ T cell or DO11.10-GFP 
hybridoma cell preparations were then introduced into the murine SMC cultures at a 1:5 ratio, for 
24, 48 and 72 h or 24 h, respectively. OVA-treated DCs, co-cultured with both OT-II CD4+ T cells 
and DO11.10-GFP hybridoma cells at the same ratio of SMCs, were used as positive control. 
Subsequently, OT-II CD4+ T cells or DO11.10-GFP hybridoma cells were collected by rinsing the 
co-cultures three times followed by staining and preparation for flow cytometric analysis. For the 
analysis of costimulatory molecule expression murine SMCs were cultured in 6 multi-well plates 
and stimulated with IFN-γ (100 ng/mL) for 72 h before flow cytometry. In a separate set of 
experiments, SMCs were stimulated with IFN-γ (100 ng/mL) for 72 h and then treated with 
fluorescein labeled-chicken OVA (FITC-OVA, 1 mg/mL, Molecular Probes) overnight. 
Subsequently, the supernatant were removed and the cells washed with PBS. The FITC-OVA 
uptake was visualized using the EVOS® FL Cell Imaging System (Life Technologies Ltd, Paisley, 
UK). 
 
2.3. Ealpha-GFP preparation and treatment. To assess the ability of murine SMCs to act as APCs, 
we employed the Ealpha (Eα)-GFP/Y-Ae system as previously described [22-24]. A recombinant 
Eschericia coli strain expressing the Eα-GFP fusion protein was grown to mid-log phase before 
induction of protein expression. Protein expression was induced by addition of Isopropil β-D-1-
tiogalattopiranoside (IPTG; Sigma-Aldrich) to a final concentration of 1mM and cultures were 
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incubated overnight at 30oC with agitation (200 rpm). The Eα-GFP fusion protein was purified from 
the bacterial lysates using HisPur Cobalt Spin Columns (Thermo Scientific, Loughborough, UK) 
and endotoxin was removed using Detoxi-Gel Endotoxin Removing Columns (Thermo Scientific). 
Murine SMCs were cultured in 6 multi-well plates, as described above, stimulated with IFN-γ (100 
ng/mL) for 72 h, and then treated with Eα-GFP (100 µg/mL). After 1, 24 and 48 h of treatment, 
cells were collected for flow cytometric analysis. DCs cultured under the same conditions and 
treated with Eα-GFP (100 µg/mL) for 24 h were used as a positive control. 
 
2.4. Flow Cytometry. Aliquots of cells were washed and resuspended in Fc block (2.4G2 hybridoma 
supernatant) for 25 mins at 4°C to block Fc receptors. Subsequently, cells were incubated with Abs 
(in PBS containing 2% FBS) for 30 mins at 4°C, washed twice and then, where necessary, 
incubated with Streptavidin for additional 20 mins at 4°C. Following washing, cells were analyzed 
on a FACScalibur using CellQuest-Pro (BD Biosciences, Oxford, UK), or on a MACSQuant 
Analyzer® (Miltenyi Biotec). Data analysis was performed using 6 FlowJo (Tree Star Inc., Olten, 
Switzerland). 
 Murine SMCs were stained with the following primary Abs: Y-Ae-Bio (specific for I-Eα 52-68 
presented on I-Ab; clone: eBioY-Ae), anti-MHC II (I-A/I-E)-APC (clone: M5/114.15.2), anti-
CD11c-APC (clone: N418), anti-CD54-PE (clone: 3E2), anti-CD44-FITC (clone: IM7), anti-
OX40L-Bio (clone: RM134L) followed by streptavidin-PerCP, anti-CD80-FITC (clone: 16-10A1), 
anti-CD40-PE (Clone: 3/23), anti-CD86-APC (clone: GL1) and anti-CD70-Bio (clone: FR70) 
followed by streptavidin-PerCP. OT-II CD4+ T cells were stained with primary mAbs anti-CD4-
PerCP (clone: RM4-5), anti-CD25-APC (clone: PC61), anti-CD44-PE (clone: IM7) and anti-CD69-
Bio (clone: H1.2F3) followed by streptavidin-Pacific Blue. DO11.10-GFP hybridoma cells were 
stained with the primary Ab anti-DO11.10 TCR-APC (clone: KJ 1-26). Isotype-matched Abs were 
used as negative control. Y-Ae Ab, anti-CD11c and anti-MHC II Ab were from eBioscience 
(Hatfield, UK), Streptavidin-Pacific Blue was from Life Technologies Ltd, all other Abs were from 
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BD Biosciences. 
 
2.5. CFSE staining. OT-II CD4+ T cells were labeled with the fluorescent dye carboxyl fluorescein 
succinimidyl ester (CFSE, Molecular Probes) as previously described [31]. The cells were washed 
and then co-cultured with SMCs or DCs (used as a positive control) for 72 h. The level of 
fluorescence intensity from the CFSE labeling was measured by flow cytometry. Incremental loss 
of CFSE intensity showed proliferation. 
 
2.6. Statistical analysis. Results are expressed as mean ± SEM of 3 experiments run in triplicate. 
The results were statistically analyzed by the t test or ANOVA (Two-Tail P value) and the 
Bonferroni post hoc test. The level of statistical significance was P<0.05 per test. 
 
3. Results 
3.1. Assessment of antigen uptake/presentation by SMCs using the Eα-GFP/Y-Ae system. 
Stimulation with IFN-γ (100 ng/mL) for 72 h resulted in a significant (P<0.01) 5 to 6 fold increase 
in the percentage of MHC class II positive SMCs compared with unstimulated cells (Figure 1(A)). 
Similar results were observed in IFN-γ-stimulated SMCs subsequently treated with Eα peptide (100 
µg/mL) for 1 and 24 h (P<0.05), while no significant changes were observed after 48 h of treatment 
(Figure 1(A)). As shown in Figure 1(B), SMC treatment with Eα peptide induced an increase in the 
percentage of GFP positive cells, both in presence or absence of IFN-γ-stimulation, being indicative 
of antigen uptake. The increase in GFP positive cells observed was significant only at 48 h 
(P<0.05). No significant changes were observed in the percentage of Y-Ae positive SMCs after 
IFN-γ-stimulation and/or treatment with Eα peptide (Figure 1(C)) suggesting that, although SMCs 
internalize the antigen, they are not able to present the Eα peptide in the context of MHC class II. 
Treatment of DCs with Eα peptide (100 µg/mL), used as positive control, caused an increase in the 
percentage of Y-Ae positive cells (Figure 1(D)). 
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3.2. SMCs fail to induce OT-II CD4+ T cell activation and proliferation. We next assessed the 
ability of SMCs to activate OVA-specific transgenic CD4+ T cells. In preliminary experiments by 
using FITC-OVA we confirmed the uptake of the model antigen by SMCs (data not shown). Using 
CFSE to track proliferation, we evaluated the number of Tg T cells undergoing proliferation after 
72 h of co-culture with SMCs or bone marrow derived DCs, used as positive control. The 
proportion of dividing T cells (expressed as percentage of CFSE- CD4+ cells) was approximately 
0.5-1% both in presence or absence of co-cultured unstimulated SMCs (Figure 2). Neither 
stimulation with IFN-γ nor treatment with OVA or OVA323-339 peptide of SMCs affected the 
proliferation of OT-II CD4+ T cells. In contrast, co-culture with OVA-treated DCs significantly 
(P<0.01) increased the proportion of dividing OT-II CD4+ T cells by around 20% (Figure 2). 
 We also examined cell surface expression of activation markers such as CD25, CD44 and CD69 
on OT-II CD4+ T cells after co-culture with SMCs or bone marrow derived DCs. CD25 and CD69 
were detected in approximately 2% of OT-II CD4+ T cells, alone or co-cultured for 24, 48 and 72 h 
with unstimulated SMCs, IFN-γ-stimulated SMCs or IFN-γ-stimulated SMCs treated with OVA or 
OVA323-339 peptide. Moreover, the percentage of CD25 and CD69 positive T cells did not change 
after SMC treatment with OVA or OVA323-339 peptide alone, while a significant (P<0.001) increase 
was observed only after co-culture with OVA-treated DCs at all of the time points considered 
(Figure 3). The percentage of CD44 positive OT-II CD4+ T cells was about 7% at all of the time 
points considered, both in presence or absence of unstimulated SMCs. Stimulation with IFN-γ 
and/or treatment of SMCs with OVA or OVA323-339 did not affect CD44 expression. A significant 
(P<0.01) increase in CD44 positive OT-II CD4+ T cells was observed after 48 and 72 h of co-
culture with OVA-treated DCs (Figure 3). These data demonstrate that antigen-pulsed aortic murine 
SMC are not able to induce antigen-specific T cell activation/proliferation. 
 
3.3. Effect of IFN-γ stimulation on costimulatory/adhesion molecules expression by murine SMCs. 
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Previous studies have correlated the inability of human SMCs to activate memory T cells with the 
lack of costimulation [19]. Thus we examined whether murine SMCs express 
costimulatory/adhesion molecules at baseline and after IFN-γ (100 ng/mL) stimulation for 72 h. As 
shown in Figure 4, unstimulated SMCs expressed CD54 (ICAM-1), CD80 and CD44 (30%, 11% 
and 87% positive cells, respectively). The stimulation with IFN-γ caused a 2 fold increase in the 
percentage of both ICAM-1 (P<0.01) and CD80 (P<0.001) positive cells while it did not affect the 
percentage of CD44 positive cells. In contrast, only low levels of OX40L, CD40, CD70 and CD86 
expression were detectable in unstimulated SMCs. IFN-γ stimulation did not increase the 
percentage of SMCs positive to these molecules. The failure of SMCs to respond to IFN-γ, in this 
case, was selective for the costimulatory molecules because the percentage of MHC class II 
molecules was increased after IFN-γ stimulation under the same conditions (Figure 4). 
 
3.4. SMCs do not activate DO11.10-GFP hybridoma cells. The murine DO11.10-GFP hybridoma 
was originally obtained by stably transfecting a DO11.10 T cell hydridoma with a construct in 
which GFP expression is under the control of a nuclear factor of activated T cells (NFAT)-regulated 
promoter [28]. Thus, once activated, hybridoma cells detectable using the KJ1-26 clonotypic 
antibody, become GFP-positive. DO11.10 hybridoma cells express the TCR recognizing OVA323–
339 peptide in the context of either I-Ad or I-Ab MHC class II [32] without any requirement for co-
stimulation [29]. Co-culture with unstimulated SMCs had no effect on GFP expression by 
DO11.10-GFP hybridoma cells and similar results were obtained after stimulation with IFN-γ 
and/or treatment of SMCs with OVA or OVA323-339 peptide. On the contrary, DCs treated with 
OVA, used as positive control, caused a significant (P<0.001) increase in GFP expression by 
hybridoma cells (Figure 5). These data confirm that SMCs are unable to present exogenous protein 
antigens in the context of MHC class II. 
 
4. Discussion 
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In the present study, we demonstrated that: (1) Cultured primary murine SMCs express MHC class 
II molecules after stimulation with IFN-γ and are able to acquire/uptake antigens; however, they fail 
to present the peptide antigen in the context of MHC class II, as demonstrated by using the specific 
Ealpha (Eα)-GFP/Y-Ae system; (2) OVA-treated SMCs fail to induce activation/proliferation of 
OT-II CD4+ T cells, data consistent with a defect in MHC class II-restricted Ag presentation and in 
the expression of costimulatory molecules, such as OX40L, CD40, CD70 and CD86; (3) SMCs also 
fail to promote activation of OVA responding DO11.10-GFP hybridoma T cells, that do not require 
any costimulatory signal for activation. 
 The first finding that murine aortic SMCs express MHC class II molecules is in line with 
previous data showing MHC class II expression in atheroma SMCs [8], in rodent arteries in 
response to injury [12], as well as in human SMCs in culture following IFN-γ-stimulation [18]. 
Murray and colleagues [18] demonstrated that Class II molecules on human saphenous vein SMCs 
were functional, since they induced CD25 expression on resting CD4+ T cells. Additional studies 
demonstrated that survival and activation of T cells occurred as a result of the specific interaction 
between TCR on T cells and MHC molecules on SMCs, since treatment with antibodies directed 
toward MHC class II blocked the proliferation of CD4+ T cells co-cultured with syngeneic SMCs 
[13, 16]. On the contrary, in the context of non-specific generalized T cell stimulation or in the 
presence of polyclonal activators such as phytohemagglutinin SMCs did not activate CD4+ T cells 
[18, 19]. 
 In order to understand whether an antigen specific stimulation leads to immunological 
competence of SMCs, engaging MHC molecules, we employed a novel and selective approach such 
as the Eα-GFP/Y-Ae model that allows visualization of antigen uptake through a GFP tagged Eα 
peptide and tracking of antigen presentation using the Y-Ae Ab. The Eα-GFP protein is 
internalized, processed by APCs to generate Eα peptide for presentation on MHC class II. The 
monoclonal Ab Y-Ae detects Eα only when bound to MHC Class II molecules (I-Ab) [21-24]. Eα-
GFP treatment of SMCs increased the percentage of GFP positive cells, without affecting the 
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percentage of SMCs positive to the monoclonal Ab Y-Ae. These results clearly demonstrate that 
primary aortic murine SMCs fail to present exogenous protein antigens in the context of MHC class 
II. 
 Our results also prove the inability of SMCs in inducing OVA specific OT-II CD4+ T cell 
activation and proliferation. A possible explanation for these observations is that SMCs fail to 
activate T cells through a failure in antigen presentation and a lack of costimulatory molecule 
expression. Indeed, although human SMCs express the co-stimulatory molecules CD44, CD54, 
CD58, and CD59 [18], they lack OX40L, considered essential for T cell activation [19]. We also 
observed lack of costimulatory molecule expression (OX40L, CD40, CD70 and CD86) on SMC 
surface following IFN-γ stimulation; supporting the hypothesis that impaired costimulation function 
contributes to the inability of SMCs to induce T cells activation/proliferation. 
 In order to analyze this point further, we co-cultured SMCs with the DO11.10-GFP hybridoma 
cells that, in presence of the model Ag OVA, undergo activation without requiring any co-
stimulatory signal [28, 29]. Importantly, SMCs failed to activate DO11.10-GFP hybridoma cells, 
demonstrating that other mechanisms, apart from a defect in costimulation function, are liable for 
the limited capacity of SMCs to activate T cells. 
 One possibility could be that SMCs cannot process protein antigens, rather than not being able 
to present them. Nevertheless, in our experiments, treatment of SMCs with OVA323-339 peptide, that 
does not require any processing to be presented in the context of MHC molecules, did not affect 
activation/proliferation of neither OT-II CD4+ T cell nor DO11.10-GFP hybridoma cells. This 
observation demonstrates that the SMC inability in presentation cannot lie in a defect in the antigen 
processing, thus further investigations will be necessary to understand the mechanisms underlining 
this deficiency. 
 
5. Conclusions 
In summary, our work demonstrates that while murine primary aortic SMCs express MHC class II 
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and can acquire exogenous antigens, they fail to activate T cells through a failure in antigen 
presentation and a lack of costimulatory molecule expression. Our results do not preclude the 
possibility that SMCs could act as APCs, depending on the environment (for example in 
atherosclerotic arteries) and the vascular bed; however they suggest that antigen presentation may 
not be the key immunological feature of SMCs in the initiation of vascular inflammation. 
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FIGURE 1: SMCs acquire exogenous antigens but fail to present them in the context of MHC class 
II. Evaluation of antigen uptake/presentation by murine SMCs. SMCs were stimulated with IFN-γ 
(100 ng/mL) for 72 h and subsequently treated with Eα-GFP peptide (100 µg/mL) for the indicated 
time points. (A) MHC class II expression. (B) GFP expression. (C) Representative flow cytometry 
plots showing no positivity of SMCs to the Y-Ae Ab or (D) positivity of DCs, used as a positive 
control. Results are expressed as mean ± SEM from three separate experiments. *P<0.05, 
**P<0.01, vs unstimulated cells. 
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FIGURE 2: SMCs fail to induce OT-II CD4+ T cell proliferation. Representative plots and relative 
statistical analysis showing the effect of SMCs on OT-II CD4+ T cell proliferation. IFN-γ-
stimulated SMCs were treated with OVA (1 mg/mL) or OVA323-339 peptide (0.5 µg/mL) overnight 
and then co-cultured with CFSE-labeled OT-II CD4+ T cells for 72 h. OVA-treated DCs were used 
as a positive control. Results are expressed as mean ± SEM from three separate experiments run in 
triplicate. **P<0.01 vs OT-II CD4+ T cells alone. 
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FIGURE 3: SMCs fail to induce OT-II CD4+ T cell activation. Expression of CD69, CD25 and 
CD44 on OT-II CD4+ T cells co-cultured with OVA- or OVA323-339 peptide-treated SMCs or OVA-
treated DCs (used as positive control). Results are expressed as mean ± SEM from three separate 
experiments run in triplicate. ***P<0.001 vs OT-II CD4+ T cells alone at 24 h; °°P<0.01, 
°°°P<0.001 vs OT-II CD4+ T cells alone at 48 h; ##P<0.01 and ###P<0.001 vs OT-II CD4+ T cells 
alone at 72 h. 
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FIGURE 4: SMCs lack key costimulatory molecules. Representative flow cytometry histograms 
and relative graph showing the effect of IFN-γ (100 ng/mL) on costimulatory/adhesion molecules 
expression in murine SMCs. Red empty histograms: Isotype control; gray filled histograms or white 
columns: unstimulated SMCs; black empty histograms or black columns: IFN-γ-stimulated SMCs. 
Results are expressed as mean ± SEM from three separate experiments run in triplicate. *P<0.05, 
**P<0.01, ***P<0.001 vs unstimulated cells. 
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FIGURE 5: Effect of SMCs on DO11.10-GFP hybridoma cell activation. IFN-γ-stimulated SMCs 
were treated with (OVA, 1 mg/mL) or OVA323-339 peptide (0.5 µg/mL) overnight and then 
cocultured with DO11.10-GFP hybridoma cells for 24 h. OVA-treated DCs were used as positive 
control. Results are expressed as mean ± SEM from three separate experiments run in triplicate. 
***P<0.001 vs DO11.10-GFP hybridoma cells alone. 
